XORTX Therapeutics (XRTX) Q3 2024 earnings summary

Executive summary

• Focuses on developing therapies for progressive kidney disease, with ongoing clinical and regulatory activities in orphan and prevalent indications.

• Operates as a late-stage clinical pharmaceutical company listed on TSXV and Nasdaq.

Financial highlights

• Net loss for the nine months ended September 30, 2024 was $3.44 million, compared to $4.86 million for the same period in 2023.

• Cash balance at September 30, 2024 was $2.30 million, down from $3.45 million at December 31, 2023.

• Total assets decreased to $3.85 million from $5.47 million at year-end 2023.

• Shareholders' equity declined to $2.13 million from $4.64 million at December 31, 2023.

• Net loss per share for the nine months was $1.25, improved from $2.46 year-over-year.

Outlook and guidance

• Plans to raise additional capital to fund research, development, and clinical studies.

• Management believes additional funding can be raised as needed, but future research may be postponed if financing is not secured.

• Proceeds from recent and post-period equity offerings intended for working capital and general corporate purposes.